Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUB-040 in recurrent or progressive uterine endometrial cancer
NCT07743541Phase 2Not yet recruiting
- Sponsor
- Tubulis
- Start
- Oct 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
A Phase 2 trial of TUB-040 in endometrial cancer (EC), sponsored by Tubulis. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
TUB-040
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07743541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07743541.